NASDAQ:NCNA - NuCana Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$24.50 +0.98 (+4.17 %)
(As of 06/25/2018 01:54 AM ET)
Previous Close$24.50
Today's Range$23.00 - $24.50
52-Week Range$9.32 - $32.00
Volume12,218 shs
Average Volume27,853 shs
Market Capitalization$748.20 million
P/E Ratio-23.11
Dividend YieldN/A
BetaN/A
NuCana logoNuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematological malignancies. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Receive NCNA News and Ratings via Email

Sign-up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NCNA
CUSIPN/A
Phone44-13-1357-1111

Debt

Debt-to-Equity RatioN/A
Current Ratio34.95
Quick Ratio34.95

Price-To-Earnings

Trailing P/E Ratio-23.11
Forward P/E Ratio-21.88
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.78 per share
Price / Book6.48

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees20
Outstanding Shares31,810,000

The Truth About Cryptocurrencies

NuCana (NASDAQ:NCNA) Frequently Asked Questions

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

What price target have analysts set for NCNA?

4 brokerages have issued 12-month price targets for NuCana's shares. Their forecasts range from $23.00 to $25.00. On average, they expect NuCana's stock price to reach $24.00 in the next twelve months. View Analyst Ratings for NuCana.

Who are some of NuCana's key competitors?

Who are NuCana's key executives?

NuCana's management team includes the folowing people:
  • Prof. Christopher B. Wood, Chairman & Chief Medical Officer (Age 72)
  • Mr. Hugh S. Griffith, Founder, CEO & Director (Age 50)
  • Mr. Donald Munoz, CFO & Principal Accounting Officer (Age 49)

When did NuCana IPO?

(NCNA) raised $100 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager.

Has NuCana been receiving favorable news coverage?

Headlines about NCNA stock have been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NuCana earned a news impact score of 0.03 on Accern's scale. They also gave media coverage about the company an impact score of 44.15 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are NuCana's major shareholders?

NuCana's stock is owned by many different of retail and institutional investors. Top institutional investors include Sofinnova Ventures Inc (14.67%), Baillie Gifford & Co. (2.02%), Alps Advisors Inc. (0.13%), Asymmetry Capital Management L.P. (0.13%), Millennium Management LLC (0.04%) and Citadel Advisors LLC (0.04%). View Institutional Ownership Trends for NuCana.

Which major investors are selling NuCana stock?

NCNA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Citadel Advisors LLC. View Insider Buying and Selling for NuCana.

Which major investors are buying NuCana stock?

NCNA stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Baillie Gifford & Co., Asymmetry Capital Management L.P. and Alps Advisors Inc.. View Insider Buying and Selling for NuCana.

How do I buy shares of NuCana?

Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $24.50.

How big of a company is NuCana?

NuCana has a market capitalization of $748.20 million. The company earns $-29,750,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. NuCana employs 20 workers across the globe.

How can I contact NuCana?

NuCana's mailing address is 3 LOCHSIDE WAY, EDINBURGH X0, EH12 9DT. The company can be reached via phone at 44-13-1357-1111.


MarketBeat Community Rating for NuCana (NCNA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about NuCana and other stocks. Vote "Outperform" if you believe NCNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NCNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.